Product Code: GVR-3-68038-318-8
Anatomic Pathology Market Growth & Trends:
The global anatomic pathology market size is expected to reach USD 58.42 billion by 2030, according to a new report by Grand View Research, Inc.. It is expected to grow at a CAGR of 8.7% from 2023 to 2030. The advent of technology in the instruments and the protocols used during the anatomic pathological procedures is anticipated to increase the adoption rate of advanced anatomic pathological instruments.
Market players are collaborating for the refurbishment of pathology products by the incorporation of innovative disease diagnostic models. In April 2021, Leica Biosystems collaborated with Paige, an AI-based diagnostics company, for expanded access to computational pathology products for translational and clinical research. Under this partnership, Paige's AI-enabled research software and Leica Biosystems' digital pathology platform were combined. This, in turn, accelerates investments in the up-gradation of pathological equipment.
Pathology-training programs offered to pathologist trainees by public and private entities drive the market. For instance, the Accreditation Council for Graduate Medical Education accredited residency programs for anatomic pathology provide education and training to individuals via numerous teaching conferences.
The drug discovery and development application segment are expected to witness the fastest growth over the forecast period due to the shifting paradigm from conventional medicine to personalized medicine. This is primarily due to the growing reliance on discoveries of putative biomarkers for the development of personalized therapies. Ongoing pathology training programs to ensure that the pathology residents are aware of the developments taking place in the field of personalized medicine have also accelerated the market growth.
North America held the largest revenue share in 2020 owing to a large number of funding programs by public agencies and the presence of key players. Asia Pacific is expected to witness the fastest growth due to the presence of multiple associations that are engaged in conducting pathology training programs.
Key players are undertaking various strategic initiatives such as mergers & acquisitions and new product development to maintain their market presence. For instance, in May 2021, CellCarta acquired Reveal Biosciences, an AI-based pathology firm. This acquisition is aimed at expanding CellCarta's offerings in AI-enabled multi-omic data analysis services and applications.
Anatomic Pathology Market Report Highlights:
- By product and services, the consumables segment accounted for the largest share in 2022. High availability, low cost, and a frequent purchase rate of consumables contributed to the segment growth
- The instruments product and services segment is expected to witness the fastest growth over the forecast period. Technological advancements in instruments to minimize the risk of errors through the integration of novel design are expected to drive the segment
- The disease diagnosis application segment dominated the market in 2022 owing to the increasing role of anatomic pathological tools in identifying any anomalies that help diagnose a condition. The use of biomarkers for tracking and identifying infections and diseases during diagnostic processes is expected to boost the growth of the segment
- In terms of end use, the hospitals segment captured the largest share in 2022 due to an increase in the hospitalization rate that stimulates the adoption of pathological workflows for disease monitoring and diagnosis
- The diagnostic laboratories end-use segment growth is facilitated by the use of state-of-the-art laboratory equipment and instrumentation, multiple electronic interfaces, and information systems
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Products & services
- 1.1.2. Application
- 1.1.3. End use
- 1.1.4. Regional scope
- 1.1.5. Estimates and forecast timeline
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.3.1. Purchased database
- 1.3.2. GVR's internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research
- 1.4. Information or Data Analysis
- 1.5. Market Formulation & Validation
- 1.6. Model Details
- 1.7. List of Secondary Sources
- 1.8. List of Primary Sources
- 1.9. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Products & services outlook
- 2.2.2. Application outlook
- 2.2.3. End use outlook
- 2.2.4. Regional outlook
- 2.3. Competitive Insights
Chapter 3. Anatomic Pathology Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Penetration & Growth Prospect Mapping
- 3.3. Market Dynamics
- 3.3.1. Market driver analysis
- 3.3.2. Market restraint analysis
- 3.4. Anatomic Pathology Market Analysis Tools
- 3.4.1. Industry Analysis - Porter's
- 3.4.1.1. Supplier power
- 3.4.1.2. Buyer power
- 3.4.1.3. Substitution threat
- 3.4.1.4. Threat of new entrant
- 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
- 3.4.2.1. Political landscape
- 3.4.2.2. Technological landscape
- 3.4.2.3. Economic landscape
Chapter 4. Anatomic Pathology: Products & Services Estimates & Trend Analysis
- 4.1. Anatomic Pathology Market: Key Takeaways
- 4.2. Anatomic Pathology Market: Movement & Market Share Analysis, 2022 & 2030
- 4.3. Instruments
- 4.3.1. Instruments market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.3.2. Microtomes & cryostat
- 4.3.2.1. Microtomes & cryostat market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.3.3. Tissue processors
- 4.3.3.1. Tissue processors market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.3.4. Automatic stainers
- 4.3.4.1. Automatic stainers market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.3.5. Whole slide imaging (WSI) scanners
- 4.3.5.1. Whole slide imaging (WSI) scanners market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.3.6. Other products
- 4.3.6.1. Other products market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.4. Consumables
- 4.4.1. Consumables market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.4.2. Reagents & antibodies
- 4.4.2.1. Reagents & antibodies market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.4.3. Probes & kits
- 4.4.3.1. Probes & kits market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.4.4. Others
- 4.4.4.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.5. Services
- 4.5.1. Services market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Anatomic Pathology: Application Estimates & Trend Analysis
- 5.1. Anatomic Pathology Market: Key Takeaways
- 5.2. Anatomic Pathology Market: Movement & Market Share Analysis, 2022 & 2030
- 5.3. Disease Diagnosis
- 5.3.1. Disease diagnosis market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4. Drug Discovery and Development
- 5.4.1. Drug discovery and development market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.5. Others
- 5.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Anatomic Pathology: End Use Estimates & Trend Analysis
- 6.1. Anatomic Pathology Market: Key Takeaways
- 6.2. Anatomic Pathology Market: Movement & Market Share Analysis, 2022 & 2030
- 6.3. Hospitals
- 6.3.1. Hospitals market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.4. Research Laboratories
- 6.4.1. Research laboratories delivery market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.5. Diagnostic Laboratories
- 6.5.1. Diagnostic laboratories market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.6. Others
- 6.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. Anatomic Pathology Market: Regional Estimates & Trend Analysis
- 7.1. Regional Outlook
- 7.2. Anatomic Pathology Market by Region: Key Takeaways
- 7.3. North America
- 7.3.1. North America market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.3.2. U.S.
- 7.3.2.1. U.S. market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.3.3. Canada
- 7.3.3.1. Canada market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4. Europe
- 7.4.1. Europe market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.2. UK
- 7.4.2.1. UK market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.3. Germany
- 7.4.3.1. Germany market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.4. France
- 7.4.4.1. France market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.5. Italy
- 7.4.5.1. Italy market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.6. Spain
- 7.4.6.1. Spain market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.7. Sweden
- 7.4.7.1. Sweden market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.8. Norway
- 7.4.8.1. Norway market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.9. Denmark
- 7.4.9.1. Denmark market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5. Asia Pacific
- 7.5.1. Asia Pacific market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.2. Japan
- 7.5.2.1. Japan market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.3. China
- 7.5.3.1. China market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.4. India
- 7.5.4.1. India market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.5. Australia
- 7.5.5.1. Australia market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.6. Thailand
- 7.5.6.1. Thailand market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.7. South Korea
- 7.5.7.1. South Korea market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.6. Latin America
- 7.6.1. Latin America market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.6.2. Brazil
- 7.6.2.1. Brazil market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.6.3. Mexico
- 7.6.3.1. Mexico market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.6.4. Argentina
- 7.6.4.1. Argentina market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.7. MEA
- 7.7.1. MEA market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.7.2. Saudi Arabia
- 7.7.2.1. Saudi Arabia market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.7.3. South Africa
- 7.7.3.1. South Africa market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.7.4. UAE
- 7.7.4.1. UAE market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.7.5. Kuwait
- 7.7.5.1. Kuwait market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
Chapter 8. Competitive Landscape
- 8.1. Recent Developments & Impact Analysis, By Key Market Participants
- 8.2. Market Participant Categorization
- 8.2.1. Danaher
- 8.2.1.1. Company overview
- 8.2.1.2. Financial performance
- 8.2.1.3. Product benchmarking
- 8.2.1.4. Strategic initiatives
- 8.2.2. PHC Holdings Corporation
- 8.2.2.1. Company overview
- 8.2.2.2. Financial performance
- 8.2.2.3. Product benchmarking
- 8.2.2.4. Strategic initiatives
- 8.2.3. Quest Diagnostics Incorporated
- 8.2.3.1. Company overview
- 8.2.3.2. Financial performance
- 8.2.3.3. Product benchmarking
- 8.2.3.4. Strategic initiatives
- 8.2.4. Laboratory Corporation of America Holdings
- 8.2.4.1. Company overview
- 8.2.4.2. Financial performance
- 8.2.4.3. Product benchmarking
- 8.2.4.4. Strategic initiatives
- 8.2.5. F. Hoffmann-La Roche AG
- 8.2.5.1. Company overview
- 8.2.5.2. Financial performance
- 8.2.5.3. Product benchmarking
- 8.2.5.4. Strategic initiatives
- 8.2.6. Agilent Technologies, Inc.
- 8.2.6.1. Company overview
- 8.2.6.2. Financial performance
- 8.2.6.3. Product benchmarking
- 8.2.6.4. Strategic initiatives
- 8.2.7. Cardinal Health
- 8.2.7.1. Company overview
- 8.2.7.2. Financial performance
- 8.2.7.3. Product benchmarking
- 8.2.7.4. Strategic initiatives
- 8.2.8. Sakura Finetek USA, Inc.
- 8.2.8.1. Company overview
- 8.2.8.2. Financial performance
- 8.2.8.3. Product benchmarking
- 8.2.8.4. Strategic initiatives
- 8.2.9. NeoGenomics Laboratories, Inc.
- 8.2.9.1. Company overview
- 8.2.9.2. Financial performance
- 8.2.9.3. Product benchmarking
- 8.2.9.4. Strategic initiatives
- 8.2.10. BioGenex
- 8.2.10.1. Company overview
- 8.2.10.2. Financial performance
- 8.2.10.3. Product benchmarking
- 8.2.10.4. Strategic initiatives
- 8.2.11. Bio SB
- 8.2.11.1. Company overview
- 8.2.11.2. Financial performance
- 8.2.11.3. Product benchmarking
- 8.2.11.4. Strategic initiatives